| Company Name: |
Biolab Reagents |
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
|
| | elsilimomab Basic information |
| Product Name: | elsilimomab | | Synonyms: | elsilimomab;B-E8;Immunoglobulin G1, anti-(human interleukin 6) (mouse monoclonal B-E8 heavy chain), disulfide with mouse monoclonal B-E8 kappa-chain, dimer;Research Grade Elsilimomab | | CAS: | 468715-71-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![elsilimomab Structure]() |
| | elsilimomab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | elsilimomab Usage And Synthesis |
| Uses | Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA)[1][2][3]. | | IC 50 | IL-6: 1.4 nM (IC50) | | References | [1] Lee JJ, et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther. 2014 Jul;22(7):1254-1265. DOI:10.1038/mt.2014.59
[2] Burger R, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica. 2017 Feb;102(2):381-390. DOI:10.3324/haematol.2016.145060
[3] Finch DK, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807. DOI:10.1016/j.jmb.2011.06.031 |
| | elsilimomab Preparation Products And Raw materials |
|